Compare Inovio Pharmaceuticals Inc (INO) vs Abrdn Physical Platinum Shares ETF (PPLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Abrdn Physical Platinum Shares ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.11 (market cap $119.42M), while Abrdn Physical Platinum Shares ETF trades at $15.23 (market cap $1.93B). The key difference: Abrdn Physical Platinum Shares ETF is far larger — about 16.2× Inovio Pharmaceuticals Inc's market cap, and Abrdn Physical Platinum Shares ETF is more actively traded (2,947,556 versus 2,789,649). Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Abrdn Physical Platinum Shares ETF for 42 Days on average.
| INO | PPLT | |
|---|---|---|
Market Cap | $119.42M | $1.93B |
Volume | 2,789,649 | 2,947,556 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $2.65 | $25.23 |
52-Week Low | $0.66 | $13.73 |
Typical Hold Time | 43 Days | 42 Days |
Enterprise Value | $90.75M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.09, down 3.54% on the day, with a bearish technical signal driven by moving averages. The company reported a net loss of $84.95 million in 2025 on minimal revenue of $65,340, with negative profitability metrics, but has beaten EPS estimates in recent quarters. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107.
The investment case hinges on regulatory approval of INO-3107, with a consensus price target of $2.75 implying significant upside. However, extreme financial losses, high cash burn, and dependence on dilutive financing pose substantial risks. Analyst sentiment is cautiously optimistic but reflects high uncertainty.
PPLT, the abrdn Physical Platinum Shares ETF, is trading at $14.78, down 4.46% with a bearish technical outlook. Moving averages and oscillators signal selling pressure, though RSI levels suggest potential oversold conditions. Recent news highlights platinum's underperformance in the precious metals rally, with technical and fundamental signals pointing to continued weakness despite historical seasonal patterns.
The outlook remains cautious with bearish momentum dominating. Investment opportunity exists for contrarian investors betting on a catch-up trade in platinum, but risks include sustained supply contango and weak relative performance versus gold and silver. Key catalysts would be renewed industrial demand or shifts in precious metals sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Abrdn Physical Platinum Shares ETF
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →
